ArticleNPJ digital medicine2026
Longitudinal assessment of chorea in Huntington's disease using digital passive monitoring.
Article in NPJ digital medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Multi-Site, Prospective, Longitudinal, Cohort Study Measuring Cerebrospinal Fluid-Mutant Huntingtin Protein in Patients With Huntington's Disease
A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase III Clinical Study to Evaluate the Efficacy and Safety of Intrathecally Administered RO7234292 (RG6042) in Patients With Manifest Huntington's Disease
Who cites it
1 citing paper in PubMed.
- Nanoparticles Navigating the Blood-Brain Barrier for Neurodegenerative Therapy.International journal of nanomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chorea is a hallmark of Huntington's disease (HD), yet its clinical assessment is of limited reliability, impairing our ability to sensitively evaluate its progression. We evaluated passive monitoring for estimating the two-year evolution of upper limb chorea in HD. Across four studies, 1025 participants collected smartwatch accelerometer data during their everyday life. We developed a machine learning model anchored to in-clinic upper limb chorea and trained cross-sectionally on disease-relevant features. The final model, selected using nested cross-validation, allowed estimating the longitudinal evolution of chorea. The resulting digital passive monitoring chorea score shows a progression of 0.13 points per year (95% CI: [0.08, 0.17]), and a robust sensitivity to change across studies, avoiding biases related to in-clinic measurements. High-resolution accelerometer data collected passively during daily life can improve the measurement of chorea in HD. Clinical Trial Registry Name: ClinicalTrials.gov; Study IDs: NCT03761849 registered 2018-11-30 and NCT03664804 registered 2018-09-07.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.